Brian Cheng
Stock Analyst at JP Morgan
(1.10)
# 3,666
Out of 4,945 analysts
66
Total ratings
35.29%
Success rate
-16.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PGEN Precigen | Upgrades: Neutral | n/a | $1.85 | - | 3 | Aug 15, 2025 | |
| IMVT Immunovant | Maintains: Overweight | $40 → $37 | $15.20 | +143.42% | 3 | Aug 12, 2025 | |
| IMNM Immunome | Maintains: Overweight | $23 → $22 | $9.94 | +121.33% | 3 | Aug 7, 2025 | |
| ALLO Allogene Therapeutics | Downgrades: Neutral | n/a | $1.07 | - | 4 | Aug 4, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Neutral | $15 → $8 | $10.12 | -20.91% | 4 | May 13, 2025 | |
| CGON CG Oncology | Initiates: Overweight | $41 | $25.98 | +57.84% | 1 | May 2, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | n/a | $42.06 | - | 1 | Mar 27, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $53 → $57 | $55.03 | +3.59% | 5 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: Neutral | $45 → $13 | $10.90 | +19.27% | 4 | Feb 28, 2025 | |
| CRGX CARGO Therapeutics | Downgrades: Underweight | n/a | $4.46 | - | 2 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.96 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $18 | $14.30 | +25.92% | 2 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $28 | $7.64 | +266.49% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $3.54 | +833.52% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $1.90 | +215.79% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $125 | $7.42 | +1,584.64% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $11.75 | +27.66% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.36 | +3,745.10% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $3.19 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.65 | +823.36% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.53 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.96 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $19.23 | +342.02% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $8.45 | +148.52% | 1 | Aug 3, 2021 |
Precigen
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $1.85
Upside: -
Immunovant
Aug 12, 2025
Maintains: Overweight
Price Target: $40 → $37
Current: $15.20
Upside: +143.42%
Immunome
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $9.94
Upside: +121.33%
Allogene Therapeutics
Aug 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.07
Upside: -
iTeos Therapeutics
May 13, 2025
Downgrades: Neutral
Price Target: $15 → $8
Current: $10.12
Upside: -20.91%
CG Oncology
May 2, 2025
Initiates: Overweight
Price Target: $41
Current: $25.98
Upside: +57.84%
Ascentage Pharma Group International
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $42.06
Upside: -
Protagonist Therapeutics
Mar 4, 2025
Maintains: Overweight
Price Target: $53 → $57
Current: $55.03
Upside: +3.59%
Intellia Therapeutics
Feb 28, 2025
Downgrades: Neutral
Price Target: $45 → $13
Current: $10.90
Upside: +19.27%
CARGO Therapeutics
Jan 30, 2025
Downgrades: Underweight
Price Target: n/a
Current: $4.46
Upside: -
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $2.96
Upside: -
Dec 16, 2024
Upgrades: Overweight
Price Target: $18
Current: $14.30
Upside: +25.92%
Nov 7, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $7.64
Upside: +266.49%
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $3.54
Upside: +833.52%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $1.90
Upside: +215.79%
Mar 19, 2024
Upgrades: Neutral
Price Target: $125
Current: $7.42
Upside: +1,584.64%
Nov 14, 2023
Maintains: Overweight
Price Target: $16 → $15
Current: $11.75
Upside: +27.66%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.36
Upside: +3,745.10%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $3.19
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.65
Upside: +823.36%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $1.53
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $1.96
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $19.23
Upside: +342.02%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $8.45
Upside: +148.52%